Clinical Trials Logo
  1. Home
  2. Gynecological Cancer
  3. NCT05028504

A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer — ALTER-GO-020  

Gynecological Cancer Clinical Trial

Official title:
A Single-arm, Open-label, Multi-cohort, Multi-center Phase II Clinical Study of Anlotinib Combined With Penpulimab in the Treatment of Recurrent or Metastatic Gynecological Cancer

Clinical Trial Summary

This is a single-arm, open-label, phase II clinical trial to evaluate the efficacy and safety of penpulimab combined with anlotinib in subjects with gynecological cancer, including 23 ovarian cancer，37 endometrial cancer，26 cervical cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05028504
Study type Interventional
Source Sichuan Cancer Hospital and Research Institute
Contact Guonan Zhang
Phone 86-13881866599
Email zhanggn@hotmail.com
Status Recruiting
Phase Phase 2
Start date May 10, 2022
Completion date December 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT03935698 - Physiotherapy Treatment in Women With Dyspareunia Following Gynecological Cancer: a Pilot Study N/A
Completed NCT01831089 - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Phase 1
Completed NCT01703585 - Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples
Completed NCT04694508 - Intraoperative Music Therapy in Gynecological Oncology N/A
Recruiting NCT03714581 - Laser Therapy Following Radiotherapy for Gynecological Cancer N/A
Recruiting NCT03740503 - Genomic Investigation of Unusual Responders
Completed NCT02169908 - Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin N/A
Completed NCT02026687 - Recovery and Analgesia After Surgery for Gynecological Cancer Phase 4
Not yet recruiting NCT06039306 - Perioperative Immunonutrition Under Enhanced Recovery After Surgery N/A
Active, not recruiting NCT04341480 - The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19
Recruiting NCT04236362 - A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer Phase 1/Phase 2
Recruiting NCT02906943 - Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Not yet recruiting NCT05003973 - The Effectiveness of Anti-resistance Exercise on Lower Limb Lymphoedema Among Gynecological Cancer N/A
Completed NCT03553784 - Low-Intensity CBT for Gynaecological Cancer Survivors N/A